Nektar Therapeutics (NKTR)
41.16
+0.36
(+0.88%)
USD |
NASDAQ |
Oct 09, 16:00
41.16
0.00 (0.00%)
After-Hours: 20:00
Nektar Therapeutics Cash from Operations (Quarterly) : -75.77M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -75.77M |
| March 31, 2026 | -44.30M |
| December 31, 2025 | -64.96M |
| September 30, 2025 | -48.76M |
| June 30, 2025 | -45.74M |
| March 31, 2025 | -49.05M |
| December 31, 2024 | -46.19M |
| September 30, 2024 | -43.93M |
| June 30, 2024 | -37.70M |
| March 31, 2024 | -47.89M |
| December 31, 2023 | -47.05M |
| September 30, 2023 | -42.12M |
| June 30, 2023 | -51.52M |
| March 31, 2023 | -51.92M |
| December 31, 2022 | -57.70M |
| September 30, 2022 | -82.89M |
| June 30, 2022 | -74.99M |
| March 31, 2022 | -88.42M |
| December 31, 2021 | -151.54M |
| September 30, 2021 | -101.14M |
| June 30, 2021 | -82.90M |
| March 31, 2021 | -77.08M |
| December 31, 2020 | -98.63M |
| September 30, 2020 | -52.68M |
| June 30, 2020 | -83.90M |
| Date | Value |
|---|---|
| March 31, 2020 | -78.08M |
| December 31, 2019 | -125.22M |
| September 30, 2019 | -68.64M |
| June 30, 2019 | -53.92M |
| March 31, 2019 | -80.90M |
| December 31, 2018 | -117.55M |
| September 30, 2018 | -71.41M |
| June 30, 2018 | 959.64M |
| March 31, 2018 | -52.47M |
| December 31, 2017 | -80.40M |
| September 30, 2017 | 93.08M |
| June 30, 2017 | -58.52M |
| March 31, 2017 | -34.57M |
| December 31, 2016 | -52.41M |
| September 30, 2016 | -27.36M |
| June 30, 2016 | -13.60M |
| March 31, 2016 | -23.65M |
| December 31, 2015 | -75.11M |
| September 30, 2015 | -14.03M |
| June 30, 2015 | -47.26M |
| March 31, 2015 | 63.31M |
| December 31, 2014 | -24.63M |
| September 30, 2014 | -46.00M |
| June 30, 2014 | -9.085M |
| March 31, 2014 | -62.29M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Eli Lilly & Co. | 10.69B |
| Inovio Pharmaceuticals, Inc. | -18.05M |
| Tonix Pharmaceuticals Holding Corp. | -41.87M |
| Capricor Therapeutics, Inc. | -31.49M |
| Kyntra Bio, Inc. | -3.991M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -399.11M |
| Cash from Financing (Quarterly) | 364.57M |
| Free Cash Flow | -234.03M |
| Free Cash Flow Per Share (Quarterly) | -2.295 |
| Free Cash Flow to Equity (Quarterly) | -68.37M |
| Free Cash Flow to Firm (Quarterly) | -68.66M |
| Free Cash Flow Yield | -23.44% |